Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36645718)

  • 1. Whole-exome sequencing of rectal neuroendocrine tumors.
    Li Y; Guo Y; Cheng Z; Tian C; Chen Y; Chen R; Yu F; Shi Y; Su F; Zhao S; Wang Z; Luo J; Tan H
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 36645718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms.
    Duan X; Zhao M; Yin X; Mi L; Shi J; Li N; Han X; Han G; Wang J; Hou J; Yin F
    Cancer Med; 2023 Aug; 12(15):16207-16220. PubMed ID: 37387515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
    Park HY; Kwon MJ; Kang HS; Kim YJ; Kim NY; Kim MJ; Min KW; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Lee HK
    Hum Pathol; 2019 May; 87():83-94. PubMed ID: 30851333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
    Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
    Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours.
    Samsom KG; Levy S; van Veenendaal LM; Roepman P; Kodach LL; Steeghs N; Valk GD; Wouter Dercksen M; Kuhlmann KFD; Verbeek WHM; Meijer GA; Tesselaar MET; van den Berg JG
    Histopathology; 2021 Mar; 78(4):556-566. PubMed ID: 32931025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
    Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
    Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
    Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Low Tumor Mutational Burden and
    Chida K; Kawazoe A; Kawazu M; Suzuki T; Nakamura Y; Nakatsura T; Kuwata T; Ueno T; Kuboki Y; Kotani D; Kojima T; Taniguchi H; Mano H; Ikeda M; Shitara K; Endo I; Yoshino T
    Clin Cancer Res; 2021 Jul; 27(13):3714-3724. PubMed ID: 33926917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole genome sequencing of colorectal neuroendocrine tumors and in-depth mutational analyses.
    Wang TT; Lu J; Xu L; Wu H; Lin D; Wu Z; Xiao Y
    Med Oncol; 2020 May; 37(6):56. PubMed ID: 32424617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
    Li K; Liu Y; Han J; Gui J; Zhang X
    Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome Sequencing and CNV Analysis on Chromosome 18 in Small Intestinal Neuroendocrine Tumors: Ruling Out a Suspect?
    Delgado Verdugo A; Crona J; Maharjan R; Hellman P; Westin G; Björklund P
    Horm Metab Res; 2015 Jun; 47(6):452-5. PubMed ID: 25354328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
    Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
    ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.